{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:48Z","timestamp":1791312948886,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.dmd.2025.100037","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:04:15Z","timestamp":1736294655000},"page":"100037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cannabidiol and \u03949-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: Implications for predicting complex cannabinoid\u2013drug interactions"],"prefix":"10.1016","volume":"53","author":[{"given":"Ankit","family":"Balhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9541-3199","authenticated-orcid":false,"given":"Yik Pui","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-8455","authenticated-orcid":false,"given":"Jashvant D.","family":"Unadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100037_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000220750","article-title":"Kinetic studies on rifampicin","volume":"16","author":"Acocella","year":"1971","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dmd.2025.100037_bib2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jinorgbio.2018.03.016","article-title":"Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2","volume":"184","author":"Arnold","year":"2018","journal-title":"J\u00a0Inorg Biochem"},{"key":"10.1016\/j.dmd.2025.100037_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fnbeh.2020.00032","article-title":"Cannabidiol (CBD) inhibited rhodamine-123 efflux in cultured vascular endothelial cells and astrocytes under hypoxic conditions","volume":"14","author":"Auzmendi","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.dmd.2025.100037_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.122.001128","article-title":"A\u00a0physiologically-based pharmacokinetic model for cannabidiol in healthy adults, hepatically-impaired adults, and children","volume":"51","author":"Bansal","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2021.35.S1.03854","article-title":"Can cannabinoids precipitate UGT-mediated drug interactions?","volume":"35","author":"Bansal","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.dmd.2025.100037_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/dmd.121.000734","article-title":"Comprehensive predictions of cytochrome P450 (P450)-mediated in\u00a0vivo cannabinoid-drug interactions based on reversible and time-dependent P450 inhibition in human liver microsomes","volume":"50","author":"Bansal","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100037_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1398462","article-title":"Cannabidiol promotes intestinal cholesterol uptake mediated by Pregnane X receptor","volume":"15","author":"Brown","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.dmd.2025.100037_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00196109","article-title":"Smoking and body weight influence the clearance of chlorpromazine","volume":"46","author":"Chetty","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100037_bib12","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ajhp\/zxaa268","article-title":"Warfarin dose adjustment required after cannabidiol initiation and titration","volume":"77","author":"Cortopassi","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.dmd.2025.100037_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.transproceed.2023.11.013","article-title":"Drug-drug interaction between cannabidiol, cyclosporine, and mycophenolate mofetil: a case report","volume":"56","author":"Cu\u00f1etti","year":"2024","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmd.2025.100037_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1124\/dmd.107.016089","article-title":"Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions","volume":"35","author":"Dixit","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2019.11.017","article-title":"Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex","volume":"105","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.dmd.2025.100037_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2013.170","article-title":"Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in\u00a0vitro CYP3A4 mRNA induction data","volume":"95","author":"Einolf","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100037_bib18","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1124\/dmd.110.033126","article-title":"Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting Pregnane X receptor-activated induction of drug-metabolizing enzymes","volume":"38","author":"Fahmi","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib19","article-title":"The impact of recreational cannabis legalization on cannabis use and associated outcomes: a systematic review","volume":"17","author":"Farrelly","year":"2023","journal-title":"Subst Abuse"},{"key":"10.1016\/j.dmd.2025.100037_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ebcr.2017.10.001","article-title":"An interaction between warfarin and cannabidiol, a case report","volume":"9","author":"Grayson","year":"2018","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.dmd.2025.100037_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1124\/dmd.116.074567","article-title":"Considerations from the IQ Induction Working Group in response to drug-drug interaction guidance from regulatory agencies: focus on downregulation, CYP2C induction, and CYP2B6 positive control","volume":"45","author":"Hariparsad","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib23","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1080\/00498250701534893","article-title":"Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro\u2013in vivo correlations","volume":"37","author":"Hewitt","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmd.2025.100037_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdermsci.2023.01.008","article-title":"Cannabidiol mediates epidermal terminal differentiation and redox homeostasis through aryl hydrocarbon receptor (AhR)-dependent signaling","volume":"109","author":"Jang","year":"2023","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.dmd.2025.100037_bib25","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.2600681106","article-title":"Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol","volume":"68","author":"Jusko","year":"1979","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmd.2025.100037_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt1978244406","article-title":"Enhanced biotransformation of theophylline in marihuana and tobacco smokers","volume":"24","author":"Jusko","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100037_bib27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/ijms19030882","article-title":"Prediction of tacrolimus exposure by CYP3A5 genotype and exposure of co-administered everolimus in japanese renal transplant recipients","volume":"19","author":"Kagaya","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmd.2025.100037_bib28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the innovation and Quality Induction Working Group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in\u00a0vitro response thresholds, variability, and clinical relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100037_bib30","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3390\/biomedicines11102630","article-title":"Therapeutic potential of cannabis: a comprehensive review of current and future applications","volume":"11","author":"Leinen","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.dmd.2025.100037_bib31","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dmd.2025.100037_bib32","first-page":"72","article-title":"Delta-9-Tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers","volume":"173","author":"Lemberger","year":"1971","journal-title":"Science (1979)"},{"key":"10.1016\/j.dmd.2025.100037_bib34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1124\/dmd.109.026526","article-title":"Evaluation of multiple in\u00a0vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, Pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells","volume":"37","author":"McGinnity","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A\u00a0phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dmd.2025.100037_bib36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.121.000530","article-title":"Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib37","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with Implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1124\/dmd.120.000322","article-title":"Development and verification of a linked \u0394 9 -THC\/11-OH-THC physiologically based pharmacokinetic model in healthy, nonpregnant population and extrapolation to pregnant women","volume":"49","author":"Patilea-Vrana","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.119.086470","article-title":"Quantifying hepatic enzyme kinetics of (-)-\u0394 9 -tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in\u00a0vitro modeling","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13318-022-00763-y","article-title":"Characterization of correction factors to enable assessment of clinical risk from in\u00a0vitro CYP3A4 induction data and basic drug-drug interaction models","volume":"47","author":"Ramsden","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100037_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/01.tp.0000888632.96945.18","article-title":"P8.057: cannabidiol (CBD) oil and tacrolimus: the unexpected high in renal transplant recipients\u2014case series and review","volume":"106","author":"Sarkar","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.dmd.2025.100037_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100037_bib43","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40262-015-0282-2","article-title":"Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients","volume":"54","author":"Staatz","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100037_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/009127009903900508","article-title":"Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction","volume":"39","author":"Tran","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100037_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/pharmaceutics16020285","article-title":"Dysregulation of the mRNA expression of human renal drug transporters by proinflammatory cytokines in primary human proximal tubular epithelial cells","volume":"16","author":"Tsang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmd.2025.100037_bib47","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3389\/fphar.2020.01142","article-title":"The clinical impact of the C0\/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients","volume":"11","author":"van Gelder","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dmd.2025.100037_bib48","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/cpdd.1262","article-title":"Pharmacokinetic drug-drug interaction with coadministration of cannabidiol and everolimus in a phase 1 healthy volunteer trial","volume":"12","author":"Wray","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dmd.2025.100037_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lfs.2015.07.007","article-title":"Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells","volume":"136","author":"Yamaori","year":"2015","journal-title":"Life Sci"},{"key":"10.1016\/j.dmd.2025.100037_bib50","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.bcp.2010.01.028","article-title":"Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes","volume":"79","author":"Yamaori","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100037_bib51","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1124\/dmd.111.041384","article-title":"Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6","volume":"39","author":"Yamaori","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100037_bib52","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.105.098541","article-title":"Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2025.100037_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-200205000-00008","article-title":"Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine","volume":"17","author":"Zullino","year":"2002","journal-title":"Int Clin Psychopharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:05:06Z","timestamp":1742331906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0090955625001126"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100037","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol and \u03949-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: Implications for predicting complex cannabinoid\u2013drug interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100037"}}